Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis

Jack H. Simon, Lawrence D. Jacobs, Marilyn Campion, Karl Wende, Nancy Simonian, Diane L. Cookfair, Richard A. Rudick, Robert M. Herndon, John R. Richert, Andres M. Salazar, John J. Alam, Jill S. Fischer, Donald E. Goodkin, Carl V. Granger, Michelle Lajaunie, Anna L. Martens-Davidson, MaryJoel Meyer, Jeanelle Sheeder, Kim Choi, Ann L. Scherzinger & 15 others David M. Bartoszak, Dennis Bourdette, Jonathan Braiman, Carol M. Brownscheidle, Michael E. Coats, Stanley L. Cohan, David S. Dougherty, Revere P. Kinkel, Michele Mass, Frederick E. Munschauer, Roger L. Priore, Patrick M. Pullicino, Barbara J. Scherokman, Bianca Weinstock-Guttman, Ruth Whitham

Research output: Contribution to journalArticle

332 Citations (Scopus)

Abstract

The Multiple Sclerosis Collaborative Research Group trial was a double- blind, randomized, multicenter, phase III, placebo-controlled study of interferon β-1a (IFNβ-1a; AVONEX) in relapsing forms of multiple sclerosis. Initial magnetic resonance imaging results have been published; this report provides additional results. Treatment with IFNβ-1a, 30 μg once weekly by intramuscular injection, resulted in a significant decrease in the number of new, enlarging, and new plus enlarging T2 lesions over 2 years. The median increase in T2 lesion volume in placebo and IFNβ-1a patients was 455 and 152 mm3, respectively, at 1 year and 1,410 and 628 mm3 at 2 years, although the treatment group differences did not reach statistical significance. For active patients, defined as those with gadolinium enhancement at baseline, the median change in T2 lesion volume in placebo and IFNβ-1a patients was 1,578 and -12 mm3 and 2,980 and 1,285 mm3 at 1 and 2 years, respectively. Except for a minimal correlation of 0.30 between relapse rate and the number of gadolinium-enhanced lesions, correlations between MR and clinical measures at baseline and throughout the study were in general poor. Once weekly intramuscular IFNβ-1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long- term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalAnnals of Neurology
Volume43
Issue number1
DOIs
StatePublished - Jan 1998

Fingerprint

Interferons
Multiple Sclerosis
Magnetic Resonance Spectroscopy
Placebos
Gadolinium
Intramuscular Injections
Magnetic Resonance Imaging
Recurrence
Therapeutics
Research

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. / Simon, Jack H.; Jacobs, Lawrence D.; Campion, Marilyn; Wende, Karl; Simonian, Nancy; Cookfair, Diane L.; Rudick, Richard A.; Herndon, Robert M.; Richert, John R.; Salazar, Andres M.; Alam, John J.; Fischer, Jill S.; Goodkin, Donald E.; Granger, Carl V.; Lajaunie, Michelle; Martens-Davidson, Anna L.; Meyer, MaryJoel; Sheeder, Jeanelle; Choi, Kim; Scherzinger, Ann L.; Bartoszak, David M.; Bourdette, Dennis; Braiman, Jonathan; Brownscheidle, Carol M.; Coats, Michael E.; Cohan, Stanley L.; Dougherty, David S.; Kinkel, Revere P.; Mass, Michele; Munschauer, Frederick E.; Priore, Roger L.; Pullicino, Patrick M.; Scherokman, Barbara J.; Weinstock-Guttman, Bianca; Whitham, Ruth.

In: Annals of Neurology, Vol. 43, No. 1, 01.1998, p. 79-87.

Research output: Contribution to journalArticle

Simon, JH, Jacobs, LD, Campion, M, Wende, K, Simonian, N, Cookfair, DL, Rudick, RA, Herndon, RM, Richert, JR, Salazar, AM, Alam, JJ, Fischer, JS, Goodkin, DE, Granger, CV, Lajaunie, M, Martens-Davidson, AL, Meyer, M, Sheeder, J, Choi, K, Scherzinger, AL, Bartoszak, DM, Bourdette, D, Braiman, J, Brownscheidle, CM, Coats, ME, Cohan, SL, Dougherty, DS, Kinkel, RP, Mass, M, Munschauer, FE, Priore, RL, Pullicino, PM, Scherokman, BJ, Weinstock-Guttman, B & Whitham, R 1998, 'Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis', Annals of Neurology, vol. 43, no. 1, pp. 79-87. https://doi.org/10.1002/ana.410430114
Simon, Jack H. ; Jacobs, Lawrence D. ; Campion, Marilyn ; Wende, Karl ; Simonian, Nancy ; Cookfair, Diane L. ; Rudick, Richard A. ; Herndon, Robert M. ; Richert, John R. ; Salazar, Andres M. ; Alam, John J. ; Fischer, Jill S. ; Goodkin, Donald E. ; Granger, Carl V. ; Lajaunie, Michelle ; Martens-Davidson, Anna L. ; Meyer, MaryJoel ; Sheeder, Jeanelle ; Choi, Kim ; Scherzinger, Ann L. ; Bartoszak, David M. ; Bourdette, Dennis ; Braiman, Jonathan ; Brownscheidle, Carol M. ; Coats, Michael E. ; Cohan, Stanley L. ; Dougherty, David S. ; Kinkel, Revere P. ; Mass, Michele ; Munschauer, Frederick E. ; Priore, Roger L. ; Pullicino, Patrick M. ; Scherokman, Barbara J. ; Weinstock-Guttman, Bianca ; Whitham, Ruth. / Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. In: Annals of Neurology. 1998 ; Vol. 43, No. 1. pp. 79-87.
@article{f90081552c3d4df9954b059b96ec2bc6,
title = "Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis",
abstract = "The Multiple Sclerosis Collaborative Research Group trial was a double- blind, randomized, multicenter, phase III, placebo-controlled study of interferon β-1a (IFNβ-1a; AVONEX) in relapsing forms of multiple sclerosis. Initial magnetic resonance imaging results have been published; this report provides additional results. Treatment with IFNβ-1a, 30 μg once weekly by intramuscular injection, resulted in a significant decrease in the number of new, enlarging, and new plus enlarging T2 lesions over 2 years. The median increase in T2 lesion volume in placebo and IFNβ-1a patients was 455 and 152 mm3, respectively, at 1 year and 1,410 and 628 mm3 at 2 years, although the treatment group differences did not reach statistical significance. For active patients, defined as those with gadolinium enhancement at baseline, the median change in T2 lesion volume in placebo and IFNβ-1a patients was 1,578 and -12 mm3 and 2,980 and 1,285 mm3 at 1 and 2 years, respectively. Except for a minimal correlation of 0.30 between relapse rate and the number of gadolinium-enhanced lesions, correlations between MR and clinical measures at baseline and throughout the study were in general poor. Once weekly intramuscular IFNβ-1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long- term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions.",
author = "Simon, {Jack H.} and Jacobs, {Lawrence D.} and Marilyn Campion and Karl Wende and Nancy Simonian and Cookfair, {Diane L.} and Rudick, {Richard A.} and Herndon, {Robert M.} and Richert, {John R.} and Salazar, {Andres M.} and Alam, {John J.} and Fischer, {Jill S.} and Goodkin, {Donald E.} and Granger, {Carl V.} and Michelle Lajaunie and Martens-Davidson, {Anna L.} and MaryJoel Meyer and Jeanelle Sheeder and Kim Choi and Scherzinger, {Ann L.} and Bartoszak, {David M.} and Dennis Bourdette and Jonathan Braiman and Brownscheidle, {Carol M.} and Coats, {Michael E.} and Cohan, {Stanley L.} and Dougherty, {David S.} and Kinkel, {Revere P.} and Michele Mass and Munschauer, {Frederick E.} and Priore, {Roger L.} and Pullicino, {Patrick M.} and Scherokman, {Barbara J.} and Bianca Weinstock-Guttman and Ruth Whitham",
year = "1998",
month = "1",
doi = "10.1002/ana.410430114",
language = "English (US)",
volume = "43",
pages = "79--87",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis

AU - Simon, Jack H.

AU - Jacobs, Lawrence D.

AU - Campion, Marilyn

AU - Wende, Karl

AU - Simonian, Nancy

AU - Cookfair, Diane L.

AU - Rudick, Richard A.

AU - Herndon, Robert M.

AU - Richert, John R.

AU - Salazar, Andres M.

AU - Alam, John J.

AU - Fischer, Jill S.

AU - Goodkin, Donald E.

AU - Granger, Carl V.

AU - Lajaunie, Michelle

AU - Martens-Davidson, Anna L.

AU - Meyer, MaryJoel

AU - Sheeder, Jeanelle

AU - Choi, Kim

AU - Scherzinger, Ann L.

AU - Bartoszak, David M.

AU - Bourdette, Dennis

AU - Braiman, Jonathan

AU - Brownscheidle, Carol M.

AU - Coats, Michael E.

AU - Cohan, Stanley L.

AU - Dougherty, David S.

AU - Kinkel, Revere P.

AU - Mass, Michele

AU - Munschauer, Frederick E.

AU - Priore, Roger L.

AU - Pullicino, Patrick M.

AU - Scherokman, Barbara J.

AU - Weinstock-Guttman, Bianca

AU - Whitham, Ruth

PY - 1998/1

Y1 - 1998/1

N2 - The Multiple Sclerosis Collaborative Research Group trial was a double- blind, randomized, multicenter, phase III, placebo-controlled study of interferon β-1a (IFNβ-1a; AVONEX) in relapsing forms of multiple sclerosis. Initial magnetic resonance imaging results have been published; this report provides additional results. Treatment with IFNβ-1a, 30 μg once weekly by intramuscular injection, resulted in a significant decrease in the number of new, enlarging, and new plus enlarging T2 lesions over 2 years. The median increase in T2 lesion volume in placebo and IFNβ-1a patients was 455 and 152 mm3, respectively, at 1 year and 1,410 and 628 mm3 at 2 years, although the treatment group differences did not reach statistical significance. For active patients, defined as those with gadolinium enhancement at baseline, the median change in T2 lesion volume in placebo and IFNβ-1a patients was 1,578 and -12 mm3 and 2,980 and 1,285 mm3 at 1 and 2 years, respectively. Except for a minimal correlation of 0.30 between relapse rate and the number of gadolinium-enhanced lesions, correlations between MR and clinical measures at baseline and throughout the study were in general poor. Once weekly intramuscular IFNβ-1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long- term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions.

AB - The Multiple Sclerosis Collaborative Research Group trial was a double- blind, randomized, multicenter, phase III, placebo-controlled study of interferon β-1a (IFNβ-1a; AVONEX) in relapsing forms of multiple sclerosis. Initial magnetic resonance imaging results have been published; this report provides additional results. Treatment with IFNβ-1a, 30 μg once weekly by intramuscular injection, resulted in a significant decrease in the number of new, enlarging, and new plus enlarging T2 lesions over 2 years. The median increase in T2 lesion volume in placebo and IFNβ-1a patients was 455 and 152 mm3, respectively, at 1 year and 1,410 and 628 mm3 at 2 years, although the treatment group differences did not reach statistical significance. For active patients, defined as those with gadolinium enhancement at baseline, the median change in T2 lesion volume in placebo and IFNβ-1a patients was 1,578 and -12 mm3 and 2,980 and 1,285 mm3 at 1 and 2 years, respectively. Except for a minimal correlation of 0.30 between relapse rate and the number of gadolinium-enhanced lesions, correlations between MR and clinical measures at baseline and throughout the study were in general poor. Once weekly intramuscular IFNβ-1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long- term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions.

UR - http://www.scopus.com/inward/record.url?scp=6844250787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844250787&partnerID=8YFLogxK

U2 - 10.1002/ana.410430114

DO - 10.1002/ana.410430114

M3 - Article

VL - 43

SP - 79

EP - 87

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -